| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 10979 | 2021 |
| Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets H Beltran, DS Rickman, K Park, SS Chae, A Sboner, TY MacDonald, ... Cancer discovery 1 (6), 487-495, 2011 | 987 | 2011 |
| Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer JA Locke, ES Guns, AA Lubik, HH Adomat, SC Hendy, CA Wood, ... Cancer research 68 (15), 6407-6415, 2008 | 954 | 2008 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 875* | 2018 |
| Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development M Gironella, M Seux, MJ Xie, C Cano, R Tomasini, J Gommeaux, S Garcia, ... Proceedings of the National Academy of Sciences 104 (41), 16170-16175, 2007 | 723 | 2007 |
| The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis CE Massie, A Lynch, A Ramos‐Montoya, J Boren, R Stark, L Fazli, ... The EMBO journal 30 (13), 2719-2733, 2011 | 708 | 2011 |
| Genomic hallmarks and structural variation in metastatic prostate cancer DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ... Cell 174 (3), 758-769. e9, 2018 | 687 | 2018 |
| Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ... Journal of Clinical Oncology 36 (24), 2492-2503, 2018 | 661 | 2018 |
| Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer EA Mostaghel, ST Page, DW Lin, L Fazli, IM Coleman, LD True, ... Cancer research 67 (10), 5033-5041, 2007 | 638 | 2007 |
| Derivation of androgen‐independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells HC Wu, JT Hsieh, ME Gleave, NM Brown, S Pathak, LWK Chung International journal of cancer 57 (3), 406-412, 1994 | 635 | 1994 |
| Acceleration of Human Prostate Cancer Growth in Vivo by Factors Produced by Prostate and Bone Fibroblasts M Gleave, JT Hsieh, C Gao, AC Von Eschenbach, LWK Chung Cancer research 51 (14), 3753-3761, 1991 | 593 | 1991 |
| Active surveillance of small renal masses: progression patterns of early stage kidney cancer MAS Jewett, K Mattar, J Basiuk, CG Morash, SE Pautler, DR Siemens, ... European urology 60 (1), 39-44, 2011 | 567 | 2011 |
| Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells DJ Mulholland, N Kobayashi, M Ruscetti, A Zhi, LM Tran, J Huang, ... Cancer research 72 (7), 1878-1889, 2012 | 552 | 2012 |
| Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ... Clinical cancer research 21 (10), 2315-2324, 2015 | 527 | 2015 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 487 | 2018 |
| Antisense therapy for cancer ME Gleave, BP Monia Nature Reviews Cancer 5 (6), 468-479, 2005 | 463 | 2005 |
| Aggressive variants of castration-resistant prostate cancer H Beltran, S Tomlins, A Aparicio, V Arora, D Rickman, G Ayala, J Huang, ... Clinical Cancer Research 20 (11), 2846-2850, 2014 | 449 | 2014 |
| The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation G Leprivier, M Remke, B Rotblat, A Dubuc, ARF Mateo, M Kool, ... Cell 153 (5), 1064-1079, 2013 | 445 | 2013 |
| Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ... Journal of Clinical Oncology 35 (27), 3097-3104, 2017 | 421 | 2017 |
| High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development D Lin, AW Wyatt, H Xue, Y Wang, X Dong, A Haegert, R Wu, S Brahmbhatt, ... Cancer research 74 (4), 1272-1283, 2014 | 407 | 2014 |
